Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?

Basit Öğe Kaydı
dc.authoridceyan, osman/0000-0002-8832-8013
dc.authorwosidYilmaz, Turgut/S-1198-2017
dc.authorwosiddikci, seyhan/A-3311-2019
dc.authorwosidCEYLAN, OSMAN/AEB-2334-2022
dc.contributor.authorDikci, Seyhan
dc.contributor.authorCeylan, Osman Melih
dc.contributor.authorDemirel, Soner
dc.contributor.authorYilmaz, Turgut
dc.date.accessioned2024-08-04T20:44:21Z
dc.date.available2024-08-04T20:44:21Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To compare 0.5 mg and 0.625 mg of bevacizumab for treating aggressive posterior retinopathy of prematurity (AP-ROP). Methods: The medical records of patients with AP-ROP who were administered intravitreal bevacizumab (IVB) as a primary treatment at a university clinic were evaluated retrospectively. Five eyes of three patients (Group 1) who received 0.625 mg/0.025 ml IVB and 10 eyes of another five patients (Group 2) who received 0.5 mg/0.02 ml IVB were evaluated. Laser photocoagulation was used as additional treatment after relapses. Anatomic results and complications were evaluated in both groups. Results: We evaluated 15 eyes of eight patients (four girls and four boys) with a flat demarcation line at posterior zone 2 and plus disease or stage-3 disease in this study. The mean gestational age of the three babies in Group 1 was 26 +/- 1 weeks and the mean birth weight was 835.33 +/- 48.01 g. The corresponding values were 25.2 +/- 1.6 weeks and 724 +/- 139.03 g, respectively, for the five babies in Group 2. Retinal vascularization was completed at a mean postmenstrual duration of 53.6 +/- 1.5 weeks without additional treatment in the five eyes in Group 1. Laser photocoagulation for relapse was administered to five of the 10 eyes in Group 2. Retinal vascularization was completed at a mean postmenstrual duration of 47.6 +/- 1.5 weeks in the remaining five eyes. None of the patients developed complications such as cataract, glaucoma, retinal tear, retinal or vitreous hemorrhage, or retinal detachment. Conclusion: Although lower IVB doses in the treatment of AP-ROP are expected to be safer in terms of local and systemic side effects in premature infants, these patients may require additional treatment with IVB or laser photocoagulation.en_US
dc.identifier.doi10.5935/0004-2749.20180005
dc.identifier.endpage17en_US
dc.identifier.issn0004-2749
dc.identifier.issn1678-2925
dc.identifier.issue1en_US
dc.identifier.pmid29538588en_US
dc.identifier.scopus2-s2.0-85043503928en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage12en_US
dc.identifier.urihttps://doi.org/10.5935/0004-2749.20180005
dc.identifier.urihttps://hdl.handle.net/11616/98193
dc.identifier.volume81en_US
dc.identifier.wosWOS:000427401000005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherConsel Brasil Oftalmologiaen_US
dc.relation.ispartofArquivos Brasileiros De Oftalmologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRetinopathy of prematurityen_US
dc.subjectBevacizumab/administration & dosageen_US
dc.subjectLight coagulation/methodsen_US
dc.subjectVascular endothelial growth factor/antagonists & inhibitorsen_US
dc.titleWhich dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu